Top Story Today
Sun Pharma Drops $11.75 Billion on a Stock Wall Street Had Left for Dead
Sun Pharma is acquiring Organon, the Merck spinoff that had zero Buy ratings and a stock hovering near $6, for $14 per share in an all-cash deal worth $11.75 billion. That's a 103% premium and the largest overseas acquisition ever by an Indian pharma company, dwarfing the previous record. The combined entity would generate roughly $12.4 billion in revenue, vaulting Sun into the top 25 pharma companies globally. Analysts project the deal could boost Sun's earnings per share 30 to 40% by fiscal 2028, though critics note Organon's best revenue drivers are shrinking.
Why it matters: Indian pharma companies, long known as the world's generic drug factories, are becoming global acquirers of Big Pharma's cast-off portfolios. This deal is the benchmark transaction for that entire wave, proving an Indian company can finance and negotiate a $12 billion global acquisition.
Read more →Mega-Deals and M&A
Merck Pays $6.7 Billion for a Company That Ditched Its Entire Pipeline for One Cancer Drug
Terns Pharmaceuticals shelved its MASH and obesity programs to bet everything on a single leukemia drug. Merck just validated that gamble with a $6.7 billion all-cash acquisition. Analysts project peak adjusted sales of $3.4 billion for TERN-701, calling this one of Merck's best deals in its entire Keytruda-cliff shopping spree. The drug attacks resistant CML through a completely different mechanism than existing treatments.
Read more →Lilly Bets $7 Billion on CAR-T Therapy That Skips the Factory Entirely
Eli Lilly is paying up to $7 billion for Kelonia Therapeutics, a tiny biotech building technology that reprograms your immune cells inside your body, no cell extraction required. The deal (with $3.25 billion upfront) is Lilly's boldest oncology bet yet, buying a platform that could turn CAR-T therapy from a weeks-long logistical ordeal into a single IV infusion.
Read more →Gilead Drops $2.18 Billion on a 14-Month-Old Startup
Ouro Medicines launched in January 2025 with $120 million in funding. Fourteen months later, Gilead is buying it for up to $2.18 billion. The prize: an "immune reset" drug that redirects your T-cells to wipe out disease-causing B-cells. Gilead splits the cost 50/50 with partner Galapagos, keeping global commercial rights while sharing the risk.
Read more →A Family-Owned Italian Pharma Company Makes Its Biggest Buy Ever
Chiesi Group, a privately held company from Parma, Italy, is paying $1.9 billion for KalVista and its FDA-approved oral pill for hereditary angioedema attacks. It's the first pill that treats acute HAE episodes (no needles required), and the launch has been exceptional. The $27 offer came in below some analyst targets, but a narrow bidder pool limited KalVista's leverage.
Read more →Science and Regulatory Breakthroughs
The FDA Just Approved a Drug That Tricks Cancer Cells Into Eating Themselves
Twenty-five years after a Yale chemist first proposed the idea, the FDA approved Veppanu (vepdegestrant), the first-ever PROTAC drug. Instead of blocking a cancer protein, it tricks the cell's own recycling system into shredding it. The clinical results are modest (five months of progression-free survival in ESR1-mutant breast cancer), but the real story is validation of an entirely new class of medicine.
Read more →One Shot to Kill Cholesterol Forever: Lilly Pushes Gene-Editing Therapy to Phase 2
Lilly is advancing VERVE-102, a gene-editing therapy, into Phase 2 trials after a single infusion cut LDL cholesterol by 53% in early testing. The treatment permanently rewrites one letter of DNA in your liver, disabling the protein that keeps bad cholesterol high. No daily pills, no refills. It's the biggest bet yet that CRISPR-era medicine can tackle the world's leading killer.
Read more →AI Meets the Microscope
Roche Spends $1 Billion to Buy a Microscope's Brain
Roche is acquiring PathAI for up to $1.05 billion ($750 million upfront), picking up an AI pathology platform trained on millions of tissue image annotations. The play: combine PathAI's algorithms with Roche's global diagnostics infrastructure to create a one-stop shop for companion diagnostics in oncology. PathAI already works with 90% of the top 15 pharma companies.
Read more →